Usefulness of radium-223 in patients with bone metastases.

Usefulness of radium-223 in patients with bone metastases. Proc (Bayl Univ Med Cent). 2017 Oct;30(4):424-426 Authors: Gupta N, Devgan A, Bansal I, Olsavsky TD, Li S, Abdelbaki A, Kumar Y Abstract Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials. PMID: 28966451 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/28966451?dopt=Abstract

Source: Baylor University Medical Center Proceedings - October 1, 2017 Category: Universities & Medical Training Authors: Gupta N, Devgan A, Bansal I, Olsavsky TD, Li S, Abdelbaki A, Kumar Y Tags: Proc (Bayl Univ Med Cent) Source Type: research

More News: Clinical Trials | Food and Drug Administration (FDA) | Universities & Medical Training